Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Comment by Brinkleyon Mar 14, 2005 2:15pm
225 Views
Post# 8748068

RE: Keeper

RE: KeeperMilestones over the next 2 years will greatly advance the development of both STS and Exherin. In 2 years we will have Phase III data on STS. Probably be in Phase III tests of exherin with a clear indication of efficacy. It is all about progressing the value of the drugs. The more developed they are the more they are worth in a collaboration deal. The more we get for a collaboration deal the more the stock is worth. Couple that with the fact that biotech runs in 5 year cycles and we are about 5 years away from the last run on biotech. I think 2 years we will have the market on our side. Drugs that fill a huge need and large pharma scrabbling to replace their drugs comming off patent. A company like ours will be worth far more than the 90 million in market cap that it is valued at today. I beleive in the drug. Worse case scenerio the patents and work todate is worth at least the $90 million. I really don't see very much down side from here. Up side is very big. If you are trading it is probably not a stock to get in right now. But if you are looking for a huge return long term. Now is a pretty good time. Hope this elaboration clarifies my position
Bullboard Posts